Match!
Elizabeth L. Christie
University of Melbourne
22Publications
7H-index
598Citations
Publications 22
Newest
#1Elizabeth L. Christie (University of Melbourne)H-Index: 7
#2Swetansu Pattnaik (Garvan Institute of Medical Research)H-Index: 1
Last.Greg Lamb (UofU: University of Utah)
view all 10 authors...
ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cassette member involved in the cellular efflux of chemotherapeutic drugs. Here we report that ovarian and breast samples from chemotherapy treated patients are positive for multiple transcriptional fusions involving ABCB1, placing it under the control of a strong promoter while leaving its open reading frame intact. We identified 15 different transcriptional fusion partners involving ABCB1, as well as patients with multiple disti...
#1Emma Morrish (University of Melbourne)
#2Anthony Copeland (WEHI: Walter and Eliza Hall Institute of Medical Research)
Last.Donia M. Moujalled (Monash University)H-Index: 11
view all 10 authors...
Acute myeloid leukemia (AML) is an aggressive disease with a current 5-year survival rate of only ∼25%, therefore development of effective treatments towards resistant AML is urgently needed. Potential mechanisms of therapy resistance include overexpression of members of the inhibitor of apoptosis protein (IAP) family. Natural IAP antagonists such as second-mitochondria-derived activator of caspases (Smac) exist, leading to the pharmaceutical development of Smac-mimetics (SMs). The clinical SM b...
#1Lan G. Coffman (University of Pittsburgh)H-Index: 9
#2Alexander T. Pearson (UIC: University of Illinois at Chicago)H-Index: 1
Last.Ronald J. Buckanovich (University of Pittsburgh)H-Index: 26
view all 7 authors...
#1Alison E. Freimund (University of Melbourne)H-Index: 1
#2Jessica Beach (Peter MacCallum Cancer Centre)H-Index: 1
Last.David Bowtell (University of Melbourne)H-Index: 73
view all 4 authors...
#1Elizabeth L. Christie (Peter MacCallum Cancer Centre)H-Index: 7
#2Swetansu Pattnaik (Garvan Institute of Medical Research)H-Index: 1
Last.David Bowtell (Peter MacCallum Cancer Centre)H-Index: 73
view all 6 authors...
Acquired drug resistance is the major obstacle in controlling high-grade serous ovarian cancer (HGSC) and leads to poor overall survival. Comparatively little massively parallel sequencing data exist from HGSC patients with recurrent disease who have been extensively treated with chemotherapy or newer targeted agents, such as anti-angiogenics or PARP inhibitors (PARPi). We previously identified four mechanisms of acquired resistance from whole-genome sequencing (WGS) of 23 HGSC patients with rec...
#1Dale W. Garsed (University of Melbourne)H-Index: 7
#2Kathryn Alsop (Peter MacCallum Cancer Centre)H-Index: 15
Last.Elizabeth L. Christie (University of Melbourne)H-Index: 7
view all 10 authors...
Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dramatic and durable response to treatment. We sought to identify clinical, pathological, and molecular determinants of exceptional survival in women with high-grade serous cancer (HGSC), a disease associated with the majority of ovarian cancer deaths. Experimental Design: We evaluated the histories of 2,283 ovarian cancer patients and, after applying stringent clinical ...
123